Glenview Trust co Grows Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Glenview Trust co raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 152.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 16,812 shares of the company’s stock after purchasing an additional 10,162 shares during the period. Glenview Trust co’s holdings in IDEXX Laboratories were worth $6,951,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Flossbach Von Storch SE boosted its holdings in IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock valued at $195,696,000 after purchasing an additional 464,791 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after purchasing an additional 316,048 shares in the last quarter. Seilern Investment Management Ltd acquired a new position in shares of IDEXX Laboratories in the 4th quarter valued at approximately $113,104,000. Vontobel Holding Ltd. boosted its stake in shares of IDEXX Laboratories by 90.1% during the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock valued at $173,051,000 after buying an additional 198,404 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $71,893,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.18% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 2.2 %

Shares of NASDAQ IDXX opened at $415.30 on Friday. The company has a market cap of $33.78 billion, a price-to-earnings ratio of 38.92, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The stock’s 50 day simple moving average is $438.03 and its 200 day simple moving average is $447.00. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent analyst reports. Piper Sandler upped their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.